Xencor | XNCR - Pre Tax Profit


Xencor reported $-4.27M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
MacroGenics USD 16.82M 52.97M Sep/2025
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Xencor USD -4.27M 1.76M Dec/2025